Who owns your health data? This question has taken on new urgency as artificial intelligence reshapes biomedical research and global power dynamics. In April 2026, a study published in Nature Medicine highlighted how geopolitical tensions between AI superpowers are transforming access to decades-old health datasets built through public funding and patient participation. The core issue isn’t just technical—it’s about trust, equity, and the future of medicine in an era where data is both a public good and a strategic asset.
The controversy emerged when geneticist Jingyuan Fu of the University of Groningen discovered that a Chinese AI research group had acquired her team’s extensive biomedical dataset for approximately €2,000. This collection, developed over 30 years, includes genomic, transcriptomic, proteomic, and metabolomic data from 167,000 participants in the northern Netherlands—roughly 10% of the region’s population. Fu expressed pride in the dataset’s utility but unease over the asymmetry in global data sharing practices, noting that whereas China has amassed vast health data reserves, its own openness to international collaboration remains limited.
This imbalance reflects a broader trend identified in recent analyses: nations with large, accessible health datasets gain significant advantages in training robust AI models for healthcare applications. As the United States and China intensify their technological rivalry, control over high-quality biomedical data has become a defining element of national power in what some analysts describe as a emerging “digital Cold War.” Both countries are mobilizing state resources to secure leadership in AI, with data centers and research partnerships serving as critical battlegrounds.
The World Economic Forum has documented how trade restrictions and technology decoupling are accelerating this divide, particularly affecting cross-border scientific collaboration. When datasets built on public trust and funded by taxpayers move across borders under opaque conditions, it raises fundamental questions about consent, benefit-sharing, and accountability. Patients who contributed blood samples or health records for research may never know how their information is being used—or by whom.
Experts warn that without updated governance frameworks, the current scramble for health data risks undermining the very foundations of ethical biomedical research. Initiatives like the Global Alliance for Genomics and Health continue to advocate for federated data models that allow analysis without transferring raw data, preserving privacy while enabling scientific progress. Though, voluntary guidelines alone may not suffice amid intensifying geopolitical pressures.
For individuals navigating this complex landscape, practical steps include reviewing consent forms carefully, asking institutions about data sharing policies, and supporting transparency initiatives. Regulatory bodies in the European Union have strengthened protections through the General Data Protection Regulation (GDPR), which classifies health data as a special category requiring explicit consent for processing. Similar frameworks are evolving elsewhere, though enforcement and international coordination remain inconsistent.
The next key development to watch is the upcoming review of the WHO’s Global Strategy on Digital Health, scheduled for presentation at the World Health Assembly in May 2026. This update is expected to address emerging challenges in health data governance, including equity in access and protection against misuse in commercial or geopolitical contexts. Official documents will be available through the WHO website following the assembly.
As AI continues to transform healthcare, the question of who owns health data is no longer theoretical—it shapes what treatments get developed, who benefits from innovation, and whether medical progress serves the public good or narrow strategic interests. Staying informed and engaged is essential to ensuring that the biomedical data revolution upholds the principles of solidarity, transparency, and trust that have long guided medical research.
What are your thoughts on health data ownership in the age of AI? Share your perspective in the comments below, and aid spread awareness by sharing this article with others who care about the future of medicine.